SEARCH

SEARCH BY CITATION

References

  • 1
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
  • 2
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387-1395.
  • 3
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
  • 4
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003; 37: 1202-1219.
  • 5
    Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 46-53.
  • 6
    Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292-298.
    Direct Link:
  • 7
    Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13.
  • 8
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961.
    Direct Link:
  • 9
    Hindorff LA, Junkins HA, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. www.genome.gov/gwastudies. Accessed May 2010.
  • 10
    Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
  • 11
    Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520-528.
  • 12
    Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Königsrainer I, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-2623.
  • 13
    Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-1060.
  • 14
    Kollerits B, Coassin S, Kiechl S, Hunt SC, Paulweber B, Willeit J, et al. A common variant in the adiponutrin gene influences liver enzyme levels. J Med Genet 2010; 47: 116-119.
  • 15
    Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti F, et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 2010; 34: 190-194.
  • 16
    Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88-96.
  • 17
    Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010; 31: 62-70.
  • 18
    Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004; 39: 188-196.
  • 19
    Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182.
  • 20
    Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. HEPATOLOGY 2009; 49: 809-820.
  • 21
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
  • 22
    Glynn NW, Meilahn EN, Charron M, Anderson SJ, Kuller LH, Cauley JA. Determinants of bone mineral density in older men. J Bone Miner Res 1995; 10: 1769-1777.
  • 23
    WHO Multicentre Growth Reference Study Group. The WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height, and Body Mass Index-for-Age: Methods and Development. Geneva, Switzerland: World Health Organization; 2006.
  • 24
    Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 2005; 34: 1319-1328.
  • 25
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
  • 26
    He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715.
  • 27
    Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-847.
  • 28
    Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et a. Histopathology of pediatric nonalcoholic fatty liver disease. HEPATOLOGY 2005; 42: 641-649.
  • 29
    Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-2116.
  • 30
    Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. HEPATOLOGY 2009; 50: 1282-1293.
  • 31
    Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804.
  • 32
    Baulande S, Lasnier F, Lucas M, Pairault J. Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem 2001; 276: 33336-33344.
  • 33
    Liu YM, Moldes M, Bastard JP, Bruckert E, Viguerie N, Hainque B, et al. Adiponutrin: A new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab 2004; 89: 2684-2689.
  • 34
    Polson DA, Thompson MP. Macronutrient composition of the diet differentially affects leptin and adiponutrin mRNA expression in response to meal feeding. J Nutr Biochem 2004; 15: 242-246.
  • 35
    Faraj M, Beauregard G, Loizon E, Moldes M, Clement K, Tahiri Y, et al. Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin. J Endocrinol 2006; 191: 427-435.
  • 36
    Moldes M, Beauregard G, Faraj M, Peretti N, Ducluzeau PH, Laville M, et al. Adiponutrin gene is regulated by insulin and glucose in human adipose tissue. Eur J Endocrinol 2006; 155: 461-468.
  • 37
    Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 2006; 55: 148-157.
  • 38
    Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 48968-48975.
  • 39
    Johansson LE, Johansson LM, Danielsson P, Norgren S, Johansson S, Marcus C, et al. Genetic variance in the adiponutrin gene family and childhood obesity. PLoS One 2009; 4: e5327.
  • 40
    Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M. Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol 2008; 159: 577-583.
  • 41
    Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001; 29: 1165-1188.